The efficacy and safety of ²²⁵Ac-PSMA-617 in metastatic castration-resistant prostate cancer.

ABSTRACT:

Background

We aimed to report our clinical experience with the use of ²²⁵Ac-PSMA-617 in the treatment of mCRPC patients.

Methods

A retrospective analysis was conducted on 29 metastatic castration-resistant prostate cancer (mCRPC) patients treated with ²²⁵Ac-PSMA-617. Patients underwent treatment at 8-week intervals and discontinued treatment upon disease progression or the occurrence of intolerable adverse effects. We acquired ⁶⁸Ga-PSMA-11 PET/CT images and laboratory test outcomes of patients at baseline and 8 weeks following each treatment. Short-term efficacy was evaluated through the biochemical response of serum prostate-specific antigen (PSA) and molecular tumor response criteria. A follow-up was conducted to assess the long-term effect

SUBMITTER: Ma J 

PROVIDER: S-EPMC11906306 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature